News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
471,872 Results
Type
Article (29556)
Company Profile (307)
Press Release (442001)
Multimedia
Podcasts (118)
Webinars (14)
Section
Business (125872)
Career Advice (1846)
Deals (24168)
Drug Delivery (91)
Drug Development (65449)
Employer Resources (142)
FDA (11577)
Job Trends (10726)
News (227342)
Policy (20186)
Tag
2027 Biotech Bay Standard (1)
2027 Genetown Elite (1)
2027 Genetown Standard (1)
2027 Pharm Country Standard (3)
Academia (2067)
Academic (2)
Accelerated approval (28)
Adcomms (25)
Allergies (123)
Alliances (32359)
ALS (161)
Alzheimer's disease (1479)
Antibody-drug conjugate (ADC) (289)
Approvals (11825)
Artificial intelligence (409)
Autoimmune disease (141)
Automation (19)
Bankruptcy (207)
Best Places to Work (9264)
BIOSECURE Act (15)
Biosimilars (155)
Biotechnology (235)
Bladder cancer (134)
Brain cancer (56)
Breast cancer (522)
Cancer (4180)
Cardiovascular disease (328)
Career advice (1558)
Career pathing (32)
CAR-T (268)
CDC (26)
Celiac Disease (1)
Cell therapy (674)
Cervical cancer (25)
Clinical research (56001)
Collaboration (1433)
Company closure (2)
Compensation (725)
Complete response letters (55)
COVID-19 (2131)
CRISPR (93)
C-suite (674)
Cystic fibrosis (146)
Data (5559)
Decentralized trials (2)
Denatured (21)
Depression (129)
Diabetes (409)
Diagnostics (4849)
Digital health (26)
Diversity (9)
Diversity, equity & inclusion (40)
Drug discovery (232)
Drug pricing (136)
Drug shortages (21)
Duchenne muscular dystrophy (225)
Earnings (53356)
Editorial (49)
Employer branding (20)
Employer resources (129)
Events (78951)
Executive appointments (747)
FDA (14192)
Fibrodysplasia Ossificans Progressiva (6)
Friedreich's ataxia (11)
Frontotemporal dementia (22)
Funding (1233)
Gene editing (196)
Generative AI (37)
Gene therapy (577)
GLP-1 (801)
Government (3056)
Grass and pollen (3)
Guidances (326)
Healthcare (14183)
HIV (42)
Huntington's disease (46)
IgA nephropathy (82)
Immunology and inflammation (235)
Immuno-oncology (53)
Indications (99)
Infectious disease (2335)
Inflammatory bowel disease (184)
Inflation Reduction Act (14)
Influenza (83)
Intellectual property (215)
Interviews (320)
IPO (13676)
IRA (36)
Job creations (1758)
Job search strategy (1299)
JPM (58)
Kidney cancer (13)
Labor market (66)
Layoffs (404)
Leadership (31)
Legal (3503)
Liver cancer (79)
Longevity (12)
Lung cancer (572)
Lymphoma (321)
Machine learning (32)
Management (44)
Manufacturing (557)
MASH (159)
Medical device (10021)
Medtech (10056)
Mergers & acquisitions (11451)
Metabolic disorders (1072)
Multiple sclerosis (149)
NASH (21)
Neurodegenerative disease (297)
Neuropsychiatric disorders (83)
Neuroscience (2613)
Neurotech (1)
NextGen: Class of 2026 (4723)
Non-profit (3084)
Now hiring (36)
Obesity (486)
Opinion (283)
Ovarian cancer (154)
Pain (169)
Pancreatic cancer (214)
Parkinson's disease (253)
Partnered (24)
Patents (412)
Patient recruitment (430)
Peanut (52)
People (37930)
Pharmaceutical (47)
Pharmacy benefit managers (19)
Phase 1 (18295)
Phase 2 (25069)
Phase 3 (17939)
Pipeline (4519)
Policy (193)
Postmarket research (1620)
Preclinical (7730)
Press Release (47)
Prostate cancer (209)
Psychedelics (54)
Radiopharmaceuticals (274)
Rare diseases (806)
Real estate (2880)
Recruiting (64)
Regulatory (17199)
Reports (28)
Research institute (1944)
Resumes & cover letters (321)
Rett syndrome (28)
RNA editing (21)
RSV (52)
Schizophrenia (139)
Series A (210)
Series B (166)
Service/supplier (1)
Sickle cell disease (94)
Special edition (21)
Spinal muscular atrophy (152)
Sponsored (32)
Startups (2564)
State (1)
Stomach cancer (11)
Supply chain (62)
Tariffs (45)
The Weekly (95)
Vaccines (755)
Venture capital (83)
Weight loss (301)
Women's health (63)
Worklife (15)
Date
Today (82)
Last 7 days (472)
Last 30 days (1631)
Last 365 days (24365)
2026 (2694)
2025 (24664)
2024 (29801)
2023 (34431)
2022 (41003)
2021 (44241)
2020 (42577)
2019 (35935)
2018 (26209)
2017 (22737)
2016 (20033)
2015 (23780)
2014 (17297)
2013 (12872)
2012 (13473)
2011 (13803)
2010 (12290)
Location
Africa (549)
Alabama (78)
Alaska (6)
Arizona (159)
Arkansas (8)
Asia (27838)
Australia (4781)
California (9405)
Canada (2499)
China (968)
Colorado (346)
Connecticut (391)
Delaware (294)
Europe (63209)
Florida (1276)
Georgia (294)
Hawaii (3)
Idaho (34)
Illinois (603)
India (50)
Indiana (342)
Iowa (19)
Japan (327)
Kansas (103)
Kentucky (23)
Louisiana (11)
Maine (31)
Maryland (1084)
Massachusetts (7002)
Michigan (196)
Minnesota (489)
Mississippi (3)
Missouri (64)
Montana (20)
Nebraska (19)
Nevada (73)
New Hampshire (63)
New Jersey (2441)
New Mexico (21)
New York (2444)
North Carolina (1110)
North Dakota (8)
Northern California (4512)
Ohio (255)
Oklahoma (17)
Oregon (34)
Pennsylvania (1843)
Puerto Rico (15)
Rhode Island (31)
South America (739)
South Carolina (49)
South Dakota (1)
Southern California (3798)
Tennessee (111)
Texas (1364)
United States (32335)
Utah (197)
Vermont (1)
Virginia (203)
Washington D.C. (56)
Washington State (744)
West Virginia (4)
Wisconsin (75)
471,872 Results for "onl therapeutics".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
ONL Therapeutics to Present at EYENOVATE and the FLORetina–ICOOR Congress 2025
November 10, 2025
·
3 min read
Press Releases
ONL Therapeutics Announces Randomization of First Patient in Global Phase 2 GALAXY Trial of Xelafaslatide (ONL1204) in Patients with Geographic Atrophy (GA) Associated with Dry AMD
October 28, 2025
·
4 min read
Press Releases
ONL Therapeutics Announces Publication of Data from Phase 1b Study of Xelafaslatide, an Investigational Therapy for Geographic Atrophy, in Ophthalmology Science
December 10, 2025
·
4 min read
Press Releases
ONL Therapeutics Announces Multiple Presentations at Leading Ophthalmology Meetings
February 4, 2025
·
3 min read
Press Releases
ONL Therapeutics Appoints Penny Fleck as Chief Development Officer
January 8, 2025
·
3 min read
BioMidwest
ONL Therapeutics to Present at 2024 BIO CEO & Investor Conference
ONL Therapeutics, Inc. announced that David Esposito, president and chief executive officer, will present a corporate update at the BIO CEO & Investor Conference on Tuesday, February 27 at 2:30 PM ET.
February 6, 2024
·
1 min read
BioMidwest
ONL Therapeutics to Present on ONL1204 in Podium Presentation at the 47th Annual Meeting of the Macula Society
ONL Therapeutics, Inc. announced that David Zacks, M.D., Ph.D. and the Edna H. Perkiss will present an update on the company’s Phase 2 study in patients with rhegmatogenous retinal detachment at the upcoming 47th Annual Meeting of the Macula Society, being held February 7 – 10, 2024, at the La Quinta Resort & Club in Palm Springs, California.
January 23, 2024
·
3 min read
Press Releases
ONL Therapeutics Closes $65 Million in Oversubscribed Series D Financing
September 13, 2024
·
3 min read
Press Releases
ONL Therapeutics to Present at the 57th Annual Scientific Meeting of The Retina Society and EURETINA Innovation Spotlight
September 10, 2024
·
2 min read
Drug Development
ONL Therapeutics Completes Enrollment in Phase 2 Study of First-in-Class Fas-Inhibitor in Patients with Macula-Off Rhegmatogenous Retinal Detachment
ONL Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel therapies for protecting the vision of patients with retinal disease, today announced the completion of patient enrollment in its Phase 2 clinical trial of ONL1204 Ophthalmic Solution in patients with macula-off rhegmatogenous retinal detachment (RRD).
August 28, 2023
·
3 min read
1 of 47,188
Next
